Zymeworks, GSK Sign Antibody Deal For Up To $440m
This article was originally published in Scrip
Zymeworks Inc. nabbed its fourth major partner by entering into a collaboration and licensing deal with GlaxoSmithKline PLC for the development of novel Fc-engineered monoclonal and bi-specific antibodies for the treatment of various undisclosed diseases.
You may also be interested in...
Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.